Joan Connolly
Direttore Tecnico/Scientifico/R&S presso ALBIREO PHARMA, INC.
Posizioni attive di Joan Connolly
Società | Posizione | Inizio | Fine |
---|---|---|---|
ALBIREO PHARMA, INC. | Direttore Tecnico/Scientifico/R&S | 13/04/2021 | - |
Storia della carriera di Joan Connolly
Precedenti posizioni note di Joan Connolly
Società | Posizione | Inizio | Fine |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Joan Connolly
Queen's University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 3 |
Canada | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Albireo Pharma, Inc.
Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Joan Connolly
- Esperienza